Multi‐phase multi‐layer mechanistic dermal absorption (MPML MechDermA) model to predict local and systemic exposure of drug products applied on skin Article Swipe
Nikunjkumar Patel
,
James F. Clarke
,
Farzaneh Salem
,
Tariq Abdulla
,
Frederico Severino Martins
,
Sumit Arora
,
Eleftheria Tsakalozou
,
Arran Hodgkinson
,
Omid Arjmandi‐Tash
,
Sînziana Cristea
,
Priyanka Ghosh
,
Khondoker Alam
,
Sam G. Raney
,
Masoud Jamei
,
Sebastian Polak
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1002/psp4.12814
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1002/psp4.12814
Physiologically‐based pharmacokinetic models combine knowledge about physiology, drug product properties, such as physicochemical parameters, absorption, distribution, metabolism, excretion characteristics, formulation attributes, and trial design or dosing regimen to mechanistically simulate drug pharmacokinetics (PK). The current work describes the development of a multiphase, multilayer mechanistic dermal absorption (MPML MechDermA) model within the Simcyp Simulator capable of simulating uptake and permeation of drugs through human skin following application of drug products to the skin. The model was designed to account for formulation characteristics as well as body site‐ and sex‐ population variability to predict local and systemic bioavailability. The present report outlines the structure and assumptions of the MPML MechDermA model and includes results from simulations comparing absorption at multiple body sites for two compounds, caffeine and benzoic acid, formulated as solutions. Finally, a model of the Feldene (piroxicam) topical gel, 0.5% was developed and assessed for its ability to predict both plasma and local skin concentrations when compared to in vivo PK data.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1002/psp4.12814
- OA Status
- gold
- Cited By
- 29
- References
- 90
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4281612605
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4281612605Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1002/psp4.12814Digital Object Identifier
- Title
-
Multi‐phase multi‐layer mechanistic dermal absorption (MPML MechDermA) model to predict local and systemic exposure of drug products applied on skinWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-06-07Full publication date if available
- Authors
-
Nikunjkumar Patel, James F. Clarke, Farzaneh Salem, Tariq Abdulla, Frederico Severino Martins, Sumit Arora, Eleftheria Tsakalozou, Arran Hodgkinson, Omid Arjmandi‐Tash, Sînziana Cristea, Priyanka Ghosh, Khondoker Alam, Sam G. Raney, Masoud Jamei, Sebastian PolakList of authors in order
- Landing page
-
https://doi.org/10.1002/psp4.12814Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1002/psp4.12814Direct OA link when available
- Concepts
-
Bioavailability, Pharmacokinetics, Absorption (acoustics), Drug, Pharmacology, ADME, Chemistry, Cosmetics, Population, Materials science, Medicine, Organic chemistry, Environmental health, Composite materialTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
29Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 9, 2024: 11, 2023: 4, 2022: 5Per-year citation counts (last 5 years)
- References (count)
-
90Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4281612605 |
|---|---|
| doi | https://doi.org/10.1002/psp4.12814 |
| ids.doi | https://doi.org/10.1002/psp4.12814 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/35670226 |
| ids.openalex | https://openalex.org/W4281612605 |
| fwci | 3.52418629 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D001682 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Biological Availability |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D001692 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Biological Transport |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D006801 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Humans |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D008954 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Models, Biological |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D001682 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Biological Availability |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D001692 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Biological Transport |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D006801 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Humans |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D008954 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Models, Biological |
| type | article |
| title | Multi‐phase multi‐layer mechanistic dermal absorption (MPML MechDermA) model to predict local and systemic exposure of drug products applied on skin |
| biblio.issue | 8 |
| biblio.volume | 11 |
| biblio.last_page | 1084 |
| biblio.first_page | 1060 |
| topics[0].id | https://openalex.org/T10704 |
| topics[0].field.id | https://openalex.org/fields/30 |
| topics[0].field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/3003 |
| topics[0].subfield.display_name | Pharmaceutical Science |
| topics[0].display_name | Advancements in Transdermal Drug Delivery |
| topics[1].id | https://openalex.org/T10920 |
| topics[1].field.id | https://openalex.org/fields/30 |
| topics[1].field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| topics[1].score | 0.9934999942779541 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/3003 |
| topics[1].subfield.display_name | Pharmaceutical Science |
| topics[1].display_name | Advanced Drug Delivery Systems |
| topics[2].id | https://openalex.org/T10837 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9930999875068665 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2708 |
| topics[2].subfield.display_name | Dermatology |
| topics[2].display_name | Dermatology and Skin Diseases |
| is_xpac | False |
| apc_list.value | 3000 |
| apc_list.currency | USD |
| apc_list.value_usd | 3000 |
| apc_paid.value | 3000 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 3000 |
| concepts[0].id | https://openalex.org/C181389837 |
| concepts[0].level | 2 |
| concepts[0].score | 0.759896993637085 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q461809 |
| concepts[0].display_name | Bioavailability |
| concepts[1].id | https://openalex.org/C112705442 |
| concepts[1].level | 2 |
| concepts[1].score | 0.6582722663879395 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q323936 |
| concepts[1].display_name | Pharmacokinetics |
| concepts[2].id | https://openalex.org/C125287762 |
| concepts[2].level | 2 |
| concepts[2].score | 0.6258687376976013 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q1758948 |
| concepts[2].display_name | Absorption (acoustics) |
| concepts[3].id | https://openalex.org/C2780035454 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5935536026954651 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q8386 |
| concepts[3].display_name | Drug |
| concepts[4].id | https://openalex.org/C98274493 |
| concepts[4].level | 1 |
| concepts[4].score | 0.540825366973877 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[4].display_name | Pharmacology |
| concepts[5].id | https://openalex.org/C69366308 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5068219304084778 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2272286 |
| concepts[5].display_name | ADME |
| concepts[6].id | https://openalex.org/C185592680 |
| concepts[6].level | 0 |
| concepts[6].score | 0.5056161880493164 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[6].display_name | Chemistry |
| concepts[7].id | https://openalex.org/C2779717098 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4954758882522583 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q131207 |
| concepts[7].display_name | Cosmetics |
| concepts[8].id | https://openalex.org/C2908647359 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4885495603084564 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2625603 |
| concepts[8].display_name | Population |
| concepts[9].id | https://openalex.org/C192562407 |
| concepts[9].level | 0 |
| concepts[9].score | 0.2340681254863739 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q228736 |
| concepts[9].display_name | Materials science |
| concepts[10].id | https://openalex.org/C71924100 |
| concepts[10].level | 0 |
| concepts[10].score | 0.1968879997730255 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[10].display_name | Medicine |
| concepts[11].id | https://openalex.org/C178790620 |
| concepts[11].level | 1 |
| concepts[11].score | 0.1221175491809845 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q11351 |
| concepts[11].display_name | Organic chemistry |
| concepts[12].id | https://openalex.org/C99454951 |
| concepts[12].level | 1 |
| concepts[12].score | 0.0 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q932068 |
| concepts[12].display_name | Environmental health |
| concepts[13].id | https://openalex.org/C159985019 |
| concepts[13].level | 1 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q181790 |
| concepts[13].display_name | Composite material |
| keywords[0].id | https://openalex.org/keywords/bioavailability |
| keywords[0].score | 0.759896993637085 |
| keywords[0].display_name | Bioavailability |
| keywords[1].id | https://openalex.org/keywords/pharmacokinetics |
| keywords[1].score | 0.6582722663879395 |
| keywords[1].display_name | Pharmacokinetics |
| keywords[2].id | https://openalex.org/keywords/absorption |
| keywords[2].score | 0.6258687376976013 |
| keywords[2].display_name | Absorption (acoustics) |
| keywords[3].id | https://openalex.org/keywords/drug |
| keywords[3].score | 0.5935536026954651 |
| keywords[3].display_name | Drug |
| keywords[4].id | https://openalex.org/keywords/pharmacology |
| keywords[4].score | 0.540825366973877 |
| keywords[4].display_name | Pharmacology |
| keywords[5].id | https://openalex.org/keywords/adme |
| keywords[5].score | 0.5068219304084778 |
| keywords[5].display_name | ADME |
| keywords[6].id | https://openalex.org/keywords/chemistry |
| keywords[6].score | 0.5056161880493164 |
| keywords[6].display_name | Chemistry |
| keywords[7].id | https://openalex.org/keywords/cosmetics |
| keywords[7].score | 0.4954758882522583 |
| keywords[7].display_name | Cosmetics |
| keywords[8].id | https://openalex.org/keywords/population |
| keywords[8].score | 0.4885495603084564 |
| keywords[8].display_name | Population |
| keywords[9].id | https://openalex.org/keywords/materials-science |
| keywords[9].score | 0.2340681254863739 |
| keywords[9].display_name | Materials science |
| keywords[10].id | https://openalex.org/keywords/medicine |
| keywords[10].score | 0.1968879997730255 |
| keywords[10].display_name | Medicine |
| keywords[11].id | https://openalex.org/keywords/organic-chemistry |
| keywords[11].score | 0.1221175491809845 |
| keywords[11].display_name | Organic chemistry |
| language | en |
| locations[0].id | doi:10.1002/psp4.12814 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210231731 |
| locations[0].source.issn | 2163-8306 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2163-8306 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | CPT Pharmacometrics & Systems Pharmacology |
| locations[0].source.host_organization | https://openalex.org/P4310319908 |
| locations[0].source.host_organization_name | Nature Portfolio |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310319908 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | CPT: Pharmacometrics & Systems Pharmacology |
| locations[0].landing_page_url | https://doi.org/10.1002/psp4.12814 |
| locations[1].id | pmid:35670226 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | CPT: pharmacometrics & systems pharmacology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/35670226 |
| locations[2].id | pmh:oai:ruj.uj.edu.pl:item/297190 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400316 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Homo Politicus (Academy of Humanities and Economics in Lodz) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].source.host_organization_lineage | |
| locations[2].license | cc-by-nc-nd |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | info:eu-repo/semantics/article |
| locations[2].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | https://ruj.uj.edu.pl/xmlui/handle/item/297190 |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:9381913 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | CPT Pharmacometrics Syst Pharmacol |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/9381913 |
| locations[4].id | pmh:oai:doaj.org/article:afd2ab177bf7434a8488d0d0e8d82e93 |
| locations[4].is_oa | True |
| locations[4].source.id | https://openalex.org/S4306401280 |
| locations[4].source.issn | |
| locations[4].source.type | repository |
| locations[4].source.is_oa | False |
| locations[4].source.issn_l | |
| locations[4].source.is_core | False |
| locations[4].source.is_in_doaj | False |
| locations[4].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[4].source.host_organization | |
| locations[4].source.host_organization_name | |
| locations[4].source.host_organization_lineage | |
| locations[4].license | cc-by-sa |
| locations[4].pdf_url | |
| locations[4].version | submittedVersion |
| locations[4].raw_type | article |
| locations[4].license_id | https://openalex.org/licenses/cc-by-sa |
| locations[4].is_accepted | False |
| locations[4].is_published | False |
| locations[4].raw_source_name | CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 8, Pp 1060-1084 (2022) |
| locations[4].landing_page_url | https://doaj.org/article/afd2ab177bf7434a8488d0d0e8d82e93 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5113836739 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Nikunjkumar Patel |
| authorships[0].countries | GB |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210161181 |
| authorships[0].affiliations[0].raw_affiliation_string | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[0].institutions[0].id | https://openalex.org/I4210161181 |
| authorships[0].institutions[0].ror | https://ror.org/02j65kc59 |
| authorships[0].institutions[0].type | company |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210161181 |
| authorships[0].institutions[0].country_code | GB |
| authorships[0].institutions[0].display_name | Simcyp (United Kingdom) |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Nikunjkumar Patel |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[1].author.id | https://openalex.org/A5040695528 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-9417-4567 |
| authorships[1].author.display_name | James F. Clarke |
| authorships[1].countries | GB |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210161181 |
| authorships[1].affiliations[0].raw_affiliation_string | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[1].institutions[0].id | https://openalex.org/I4210161181 |
| authorships[1].institutions[0].ror | https://ror.org/02j65kc59 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210161181 |
| authorships[1].institutions[0].country_code | GB |
| authorships[1].institutions[0].display_name | Simcyp (United Kingdom) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | James F. Clarke |
| authorships[1].is_corresponding | True |
| authorships[1].raw_affiliation_strings | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[2].author.id | https://openalex.org/A5002332035 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-1791-9390 |
| authorships[2].author.display_name | Farzaneh Salem |
| authorships[2].countries | GB |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210161181 |
| authorships[2].affiliations[0].raw_affiliation_string | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[2].institutions[0].id | https://openalex.org/I4210161181 |
| authorships[2].institutions[0].ror | https://ror.org/02j65kc59 |
| authorships[2].institutions[0].type | company |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210161181 |
| authorships[2].institutions[0].country_code | GB |
| authorships[2].institutions[0].display_name | Simcyp (United Kingdom) |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Farzaneh Salem |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[3].author.id | https://openalex.org/A5111593558 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Tariq Abdulla |
| authorships[3].countries | GB |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210161181 |
| authorships[3].affiliations[0].raw_affiliation_string | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[3].institutions[0].id | https://openalex.org/I4210161181 |
| authorships[3].institutions[0].ror | https://ror.org/02j65kc59 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210161181 |
| authorships[3].institutions[0].country_code | GB |
| authorships[3].institutions[0].display_name | Simcyp (United Kingdom) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Tariq Abdulla |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[4].author.id | https://openalex.org/A5041747609 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-5555-8771 |
| authorships[4].author.display_name | Frederico Severino Martins |
| authorships[4].countries | GB |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210161181 |
| authorships[4].affiliations[0].raw_affiliation_string | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[4].institutions[0].id | https://openalex.org/I4210161181 |
| authorships[4].institutions[0].ror | https://ror.org/02j65kc59 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210161181 |
| authorships[4].institutions[0].country_code | GB |
| authorships[4].institutions[0].display_name | Simcyp (United Kingdom) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Frederico Martins |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[5].author.id | https://openalex.org/A5028850036 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-8860-667X |
| authorships[5].author.display_name | Sumit Arora |
| authorships[5].countries | GB |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210161181 |
| authorships[5].affiliations[0].raw_affiliation_string | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[5].institutions[0].id | https://openalex.org/I4210161181 |
| authorships[5].institutions[0].ror | https://ror.org/02j65kc59 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210161181 |
| authorships[5].institutions[0].country_code | GB |
| authorships[5].institutions[0].display_name | Simcyp (United Kingdom) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Sumit Arora |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[6].author.id | https://openalex.org/A5013968242 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-1993-8528 |
| authorships[6].author.display_name | Eleftheria Tsakalozou |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I1320320070, https://openalex.org/I1333606569 |
| authorships[6].affiliations[0].raw_affiliation_string | Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, Maryland, USA |
| authorships[6].institutions[0].id | https://openalex.org/I1333606569 |
| authorships[6].institutions[0].ror | https://ror.org/00yf3tm42 |
| authorships[6].institutions[0].type | facility |
| authorships[6].institutions[0].lineage | https://openalex.org/I1299022934, https://openalex.org/I1320320070, https://openalex.org/I1333606569 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Center for Drug Evaluation and Research |
| authorships[6].institutions[1].id | https://openalex.org/I1320320070 |
| authorships[6].institutions[1].ror | https://ror.org/034xvzb47 |
| authorships[6].institutions[1].type | government |
| authorships[6].institutions[1].lineage | https://openalex.org/I1299022934, https://openalex.org/I1320320070 |
| authorships[6].institutions[1].country_code | US |
| authorships[6].institutions[1].display_name | United States Food and Drug Administration |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Eleftheria Tsakalozou |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, Maryland, USA |
| authorships[7].author.id | https://openalex.org/A5074544195 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Arran Hodgkinson |
| authorships[7].countries | GB |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210161181 |
| authorships[7].affiliations[0].raw_affiliation_string | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[7].institutions[0].id | https://openalex.org/I4210161181 |
| authorships[7].institutions[0].ror | https://ror.org/02j65kc59 |
| authorships[7].institutions[0].type | company |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210161181 |
| authorships[7].institutions[0].country_code | GB |
| authorships[7].institutions[0].display_name | Simcyp (United Kingdom) |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Arran Hodgkinson |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[8].author.id | https://openalex.org/A5023909060 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Omid Arjmandi‐Tash |
| authorships[8].countries | GB |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210161181 |
| authorships[8].affiliations[0].raw_affiliation_string | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[8].institutions[0].id | https://openalex.org/I4210161181 |
| authorships[8].institutions[0].ror | https://ror.org/02j65kc59 |
| authorships[8].institutions[0].type | company |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210161181 |
| authorships[8].institutions[0].country_code | GB |
| authorships[8].institutions[0].display_name | Simcyp (United Kingdom) |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Omid Arjmandi‐Tash |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[9].author.id | https://openalex.org/A5033974419 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Sînziana Cristea |
| authorships[9].countries | GB |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210161181 |
| authorships[9].affiliations[0].raw_affiliation_string | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[9].institutions[0].id | https://openalex.org/I4210161181 |
| authorships[9].institutions[0].ror | https://ror.org/02j65kc59 |
| authorships[9].institutions[0].type | company |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210161181 |
| authorships[9].institutions[0].country_code | GB |
| authorships[9].institutions[0].display_name | Simcyp (United Kingdom) |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Sinziana Cristea |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[10].author.id | https://openalex.org/A5086989058 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-4666-7420 |
| authorships[10].author.display_name | Priyanka Ghosh |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I1320320070, https://openalex.org/I1333606569 |
| authorships[10].affiliations[0].raw_affiliation_string | Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, Maryland, USA |
| authorships[10].institutions[0].id | https://openalex.org/I1333606569 |
| authorships[10].institutions[0].ror | https://ror.org/00yf3tm42 |
| authorships[10].institutions[0].type | facility |
| authorships[10].institutions[0].lineage | https://openalex.org/I1299022934, https://openalex.org/I1320320070, https://openalex.org/I1333606569 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | Center for Drug Evaluation and Research |
| authorships[10].institutions[1].id | https://openalex.org/I1320320070 |
| authorships[10].institutions[1].ror | https://ror.org/034xvzb47 |
| authorships[10].institutions[1].type | government |
| authorships[10].institutions[1].lineage | https://openalex.org/I1299022934, https://openalex.org/I1320320070 |
| authorships[10].institutions[1].country_code | US |
| authorships[10].institutions[1].display_name | United States Food and Drug Administration |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Priyanka Ghosh |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, Maryland, USA |
| authorships[11].author.id | https://openalex.org/A5103035656 |
| authorships[11].author.orcid | https://orcid.org/0000-0001-8757-2412 |
| authorships[11].author.display_name | Khondoker Alam |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I1320320070, https://openalex.org/I1333606569 |
| authorships[11].affiliations[0].raw_affiliation_string | Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, Maryland, USA |
| authorships[11].institutions[0].id | https://openalex.org/I1333606569 |
| authorships[11].institutions[0].ror | https://ror.org/00yf3tm42 |
| authorships[11].institutions[0].type | facility |
| authorships[11].institutions[0].lineage | https://openalex.org/I1299022934, https://openalex.org/I1320320070, https://openalex.org/I1333606569 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | Center for Drug Evaluation and Research |
| authorships[11].institutions[1].id | https://openalex.org/I1320320070 |
| authorships[11].institutions[1].ror | https://ror.org/034xvzb47 |
| authorships[11].institutions[1].type | government |
| authorships[11].institutions[1].lineage | https://openalex.org/I1299022934, https://openalex.org/I1320320070 |
| authorships[11].institutions[1].country_code | US |
| authorships[11].institutions[1].display_name | United States Food and Drug Administration |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Khondoker Alam |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, Maryland, USA |
| authorships[12].author.id | https://openalex.org/A5072582475 |
| authorships[12].author.orcid | https://orcid.org/0000-0003-3562-8175 |
| authorships[12].author.display_name | Sam G. Raney |
| authorships[12].countries | US |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I1320320070, https://openalex.org/I1333606569 |
| authorships[12].affiliations[0].raw_affiliation_string | Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, Maryland, USA |
| authorships[12].institutions[0].id | https://openalex.org/I1333606569 |
| authorships[12].institutions[0].ror | https://ror.org/00yf3tm42 |
| authorships[12].institutions[0].type | facility |
| authorships[12].institutions[0].lineage | https://openalex.org/I1299022934, https://openalex.org/I1320320070, https://openalex.org/I1333606569 |
| authorships[12].institutions[0].country_code | US |
| authorships[12].institutions[0].display_name | Center for Drug Evaluation and Research |
| authorships[12].institutions[1].id | https://openalex.org/I1320320070 |
| authorships[12].institutions[1].ror | https://ror.org/034xvzb47 |
| authorships[12].institutions[1].type | government |
| authorships[12].institutions[1].lineage | https://openalex.org/I1299022934, https://openalex.org/I1320320070 |
| authorships[12].institutions[1].country_code | US |
| authorships[12].institutions[1].display_name | United States Food and Drug Administration |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Sam G. Raney |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, Maryland, USA |
| authorships[13].author.id | https://openalex.org/A5038126039 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-3443-0194 |
| authorships[13].author.display_name | Masoud Jamei |
| authorships[13].countries | GB |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210161181 |
| authorships[13].affiliations[0].raw_affiliation_string | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[13].institutions[0].id | https://openalex.org/I4210161181 |
| authorships[13].institutions[0].ror | https://ror.org/02j65kc59 |
| authorships[13].institutions[0].type | company |
| authorships[13].institutions[0].lineage | https://openalex.org/I4210161181 |
| authorships[13].institutions[0].country_code | GB |
| authorships[13].institutions[0].display_name | Simcyp (United Kingdom) |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Masoud Jamei |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[14].author.id | https://openalex.org/A5054966624 |
| authorships[14].author.orcid | https://orcid.org/0000-0001-8614-0642 |
| authorships[14].author.display_name | Sebastian Polak |
| authorships[14].countries | GB, PL |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I126596746 |
| authorships[14].affiliations[0].raw_affiliation_string | Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland |
| authorships[14].affiliations[1].institution_ids | https://openalex.org/I4210161181 |
| authorships[14].affiliations[1].raw_affiliation_string | Simcyp Division, Certara UK, Sheffield, UK |
| authorships[14].institutions[0].id | https://openalex.org/I4210161181 |
| authorships[14].institutions[0].ror | https://ror.org/02j65kc59 |
| authorships[14].institutions[0].type | company |
| authorships[14].institutions[0].lineage | https://openalex.org/I4210161181 |
| authorships[14].institutions[0].country_code | GB |
| authorships[14].institutions[0].display_name | Simcyp (United Kingdom) |
| authorships[14].institutions[1].id | https://openalex.org/I126596746 |
| authorships[14].institutions[1].ror | https://ror.org/03bqmcz70 |
| authorships[14].institutions[1].type | education |
| authorships[14].institutions[1].lineage | https://openalex.org/I126596746 |
| authorships[14].institutions[1].country_code | PL |
| authorships[14].institutions[1].display_name | Jagiellonian University |
| authorships[14].author_position | last |
| authorships[14].raw_author_name | Sebastian Polak |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland, Simcyp Division, Certara UK, Sheffield, UK |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1002/psp4.12814 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Multi‐phase multi‐layer mechanistic dermal absorption (MPML MechDermA) model to predict local and systemic exposure of drug products applied on skin |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10704 |
| primary_topic.field.id | https://openalex.org/fields/30 |
| primary_topic.field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/3003 |
| primary_topic.subfield.display_name | Pharmaceutical Science |
| primary_topic.display_name | Advancements in Transdermal Drug Delivery |
| related_works | https://openalex.org/W2349581650, https://openalex.org/W2392502762, https://openalex.org/W2349871865, https://openalex.org/W4231915261, https://openalex.org/W4238064147, https://openalex.org/W2083067870, https://openalex.org/W2148150619, https://openalex.org/W2057372812, https://openalex.org/W4205538476, https://openalex.org/W4324369038 |
| cited_by_count | 29 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 9 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 11 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 4 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 5 |
| locations_count | 5 |
| best_oa_location.id | doi:10.1002/psp4.12814 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210231731 |
| best_oa_location.source.issn | 2163-8306 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2163-8306 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | CPT Pharmacometrics & Systems Pharmacology |
| best_oa_location.source.host_organization | https://openalex.org/P4310319908 |
| best_oa_location.source.host_organization_name | Nature Portfolio |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310319908 |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | CPT: Pharmacometrics & Systems Pharmacology |
| best_oa_location.landing_page_url | https://doi.org/10.1002/psp4.12814 |
| primary_location.id | doi:10.1002/psp4.12814 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210231731 |
| primary_location.source.issn | 2163-8306 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2163-8306 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | CPT Pharmacometrics & Systems Pharmacology |
| primary_location.source.host_organization | https://openalex.org/P4310319908 |
| primary_location.source.host_organization_name | Nature Portfolio |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310319908 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | CPT: Pharmacometrics & Systems Pharmacology |
| primary_location.landing_page_url | https://doi.org/10.1002/psp4.12814 |
| publication_date | 2022-06-07 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W2027143209, https://openalex.org/W2031426306, https://openalex.org/W2990882447, https://openalex.org/W2808753212, https://openalex.org/W3128371112, https://openalex.org/W2741525634, https://openalex.org/W2783299760, https://openalex.org/W2899444542, https://openalex.org/W2914639693, https://openalex.org/W2341647963, https://openalex.org/W2040233060, https://openalex.org/W2089133581, https://openalex.org/W2103606212, https://openalex.org/W2621175742, https://openalex.org/W2996538600, https://openalex.org/W1530456667, https://openalex.org/W1561210178, https://openalex.org/W2103072677, https://openalex.org/W1604173330, https://openalex.org/W1988604034, https://openalex.org/W2883240277, https://openalex.org/W1983943677, https://openalex.org/W1594382975, https://openalex.org/W649209898, https://openalex.org/W3004516776, https://openalex.org/W2908654951, https://openalex.org/W2068911031, https://openalex.org/W2899818458, https://openalex.org/W1978924150, https://openalex.org/W3090530295, https://openalex.org/W3129436004, https://openalex.org/W2113830209, https://openalex.org/W2165334931, https://openalex.org/W2471625978, https://openalex.org/W2072044044, https://openalex.org/W2079092392, https://openalex.org/W2041477129, https://openalex.org/W2086458684, https://openalex.org/W1967743205, https://openalex.org/W2089751659, https://openalex.org/W4229903923, https://openalex.org/W2169288745, https://openalex.org/W2039161367, https://openalex.org/W2061617831, https://openalex.org/W2055368553, https://openalex.org/W59336656, https://openalex.org/W2016466978, https://openalex.org/W1975230163, https://openalex.org/W2396226001, https://openalex.org/W2742371482, https://openalex.org/W2901786480, https://openalex.org/W3027309705, https://openalex.org/W2043057808, https://openalex.org/W2072208402, https://openalex.org/W1630686444, https://openalex.org/W2072874166, https://openalex.org/W2053284430, https://openalex.org/W2401524087, https://openalex.org/W1987102234, https://openalex.org/W1981432419, https://openalex.org/W2088332475, https://openalex.org/W2105917553, https://openalex.org/W2762416511, https://openalex.org/W2165105357, https://openalex.org/W2054494843, https://openalex.org/W2090726923, https://openalex.org/W2006987912, https://openalex.org/W2894058867, https://openalex.org/W4243728537, https://openalex.org/W2074062196, https://openalex.org/W2024226000, https://openalex.org/W1976460334, https://openalex.org/W2001744270, https://openalex.org/W2073775004, https://openalex.org/W2045960810, https://openalex.org/W2106872232, https://openalex.org/W1996306415, https://openalex.org/W2558986295, https://openalex.org/W2056349938, https://openalex.org/W2951877340, https://openalex.org/W2965121532, https://openalex.org/W2035067444, https://openalex.org/W2094142374, https://openalex.org/W174346363, https://openalex.org/W1969852825, https://openalex.org/W1970582744, https://openalex.org/W2008643614, https://openalex.org/W1979074365, https://openalex.org/W1199193239, https://openalex.org/W4281612605 |
| referenced_works_count | 90 |
| abstract_inverted_index.a | 41, 132 |
| abstract_inverted_index.PK | 161 |
| abstract_inverted_index.as | 12, 82, 84, 129 |
| abstract_inverted_index.at | 117 |
| abstract_inverted_index.in | 159 |
| abstract_inverted_index.of | 40, 55, 60, 67, 105, 134 |
| abstract_inverted_index.or | 25 |
| abstract_inverted_index.to | 28, 70, 77, 91, 148, 158 |
| abstract_inverted_index.The | 34, 73, 97 |
| abstract_inverted_index.and | 22, 58, 87, 94, 103, 110, 125, 143, 152 |
| abstract_inverted_index.for | 79, 121, 145 |
| abstract_inverted_index.its | 146 |
| abstract_inverted_index.the | 38, 51, 71, 101, 106, 135 |
| abstract_inverted_index.two | 122 |
| abstract_inverted_index.was | 75, 141 |
| abstract_inverted_index.0.5% | 140 |
| abstract_inverted_index.MPML | 107 |
| abstract_inverted_index.body | 85, 119 |
| abstract_inverted_index.both | 150 |
| abstract_inverted_index.drug | 8, 31, 68 |
| abstract_inverted_index.from | 113 |
| abstract_inverted_index.gel, | 139 |
| abstract_inverted_index.skin | 64, 154 |
| abstract_inverted_index.such | 11 |
| abstract_inverted_index.vivo | 160 |
| abstract_inverted_index.well | 83 |
| abstract_inverted_index.when | 156 |
| abstract_inverted_index.work | 36 |
| abstract_inverted_index.(MPML | 47 |
| abstract_inverted_index.(PK). | 33 |
| abstract_inverted_index.about | 6 |
| abstract_inverted_index.acid, | 127 |
| abstract_inverted_index.data. | 162 |
| abstract_inverted_index.drugs | 61 |
| abstract_inverted_index.human | 63 |
| abstract_inverted_index.local | 93, 153 |
| abstract_inverted_index.model | 49, 74, 109, 133 |
| abstract_inverted_index.sites | 120 |
| abstract_inverted_index.skin. | 72 |
| abstract_inverted_index.trial | 23 |
| abstract_inverted_index.Simcyp | 52 |
| abstract_inverted_index.dermal | 45 |
| abstract_inverted_index.design | 24 |
| abstract_inverted_index.dosing | 26 |
| abstract_inverted_index.models | 3 |
| abstract_inverted_index.plasma | 151 |
| abstract_inverted_index.report | 99 |
| abstract_inverted_index.sex‐ | 88 |
| abstract_inverted_index.uptake | 57 |
| abstract_inverted_index.within | 50 |
| abstract_inverted_index.Feldene | 136 |
| abstract_inverted_index.ability | 147 |
| abstract_inverted_index.account | 78 |
| abstract_inverted_index.benzoic | 126 |
| abstract_inverted_index.capable | 54 |
| abstract_inverted_index.combine | 4 |
| abstract_inverted_index.current | 35 |
| abstract_inverted_index.predict | 92, 149 |
| abstract_inverted_index.present | 98 |
| abstract_inverted_index.product | 9 |
| abstract_inverted_index.regimen | 27 |
| abstract_inverted_index.results | 112 |
| abstract_inverted_index.site‐ | 86 |
| abstract_inverted_index.through | 62 |
| abstract_inverted_index.topical | 138 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Finally, | 131 |
| abstract_inverted_index.assessed | 144 |
| abstract_inverted_index.caffeine | 124 |
| abstract_inverted_index.compared | 157 |
| abstract_inverted_index.designed | 76 |
| abstract_inverted_index.includes | 111 |
| abstract_inverted_index.multiple | 118 |
| abstract_inverted_index.outlines | 100 |
| abstract_inverted_index.products | 69 |
| abstract_inverted_index.simulate | 30 |
| abstract_inverted_index.systemic | 95 |
| abstract_inverted_index.MechDermA | 108 |
| abstract_inverted_index.Simulator | 53 |
| abstract_inverted_index.comparing | 115 |
| abstract_inverted_index.describes | 37 |
| abstract_inverted_index.developed | 142 |
| abstract_inverted_index.excretion | 18 |
| abstract_inverted_index.following | 65 |
| abstract_inverted_index.knowledge | 5 |
| abstract_inverted_index.structure | 102 |
| abstract_inverted_index.MechDermA) | 48 |
| abstract_inverted_index.absorption | 46, 116 |
| abstract_inverted_index.compounds, | 123 |
| abstract_inverted_index.formulated | 128 |
| abstract_inverted_index.multilayer | 43 |
| abstract_inverted_index.permeation | 59 |
| abstract_inverted_index.population | 89 |
| abstract_inverted_index.simulating | 56 |
| abstract_inverted_index.solutions. | 130 |
| abstract_inverted_index.(piroxicam) | 137 |
| abstract_inverted_index.absorption, | 15 |
| abstract_inverted_index.application | 66 |
| abstract_inverted_index.assumptions | 104 |
| abstract_inverted_index.attributes, | 21 |
| abstract_inverted_index.development | 39 |
| abstract_inverted_index.formulation | 20, 80 |
| abstract_inverted_index.mechanistic | 44 |
| abstract_inverted_index.metabolism, | 17 |
| abstract_inverted_index.multiphase, | 42 |
| abstract_inverted_index.parameters, | 14 |
| abstract_inverted_index.physiology, | 7 |
| abstract_inverted_index.properties, | 10 |
| abstract_inverted_index.simulations | 114 |
| abstract_inverted_index.variability | 90 |
| abstract_inverted_index.distribution, | 16 |
| abstract_inverted_index.concentrations | 155 |
| abstract_inverted_index.characteristics | 81 |
| abstract_inverted_index.mechanistically | 29 |
| abstract_inverted_index.pharmacokinetic | 2 |
| abstract_inverted_index.physicochemical | 13 |
| abstract_inverted_index.bioavailability. | 96 |
| abstract_inverted_index.characteristics, | 19 |
| abstract_inverted_index.pharmacokinetics | 32 |
| abstract_inverted_index.Physiologically‐based | 1 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 97 |
| corresponding_author_ids | https://openalex.org/A5040695528 |
| countries_distinct_count | 3 |
| institutions_distinct_count | 15 |
| corresponding_institution_ids | https://openalex.org/I4210161181 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.6100000143051147 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.89686623 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |